Cargando…

Role of Akt signaling in resistance to DNA-targeted therapy

The Akt signal transduction pathway controls most hallmarks of cancer. Activation of the Akt cascade promotes a malignant phenotype and is also widely implicated in drug resistance. Therefore, the modulation of Akt activity is regarded as an attractive strategy to enhance the efficacy of cancer ther...

Descripción completa

Detalles Bibliográficos
Autores principales:	Avan, Abolfazl, Narayan, Ravi, Giovannetti, Elisa, Peters, Godefridus J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2016
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5056327/ https://www.ncbi.nlm.nih.gov/pubmed/27777878 http://dx.doi.org/10.5306/wjco.v7.i5.352

Ejemplares similares

c-Met as a Target for Personalized Therapy
por: Garajová, Ingrid, et al.
Publicado: (2015)

AKT1 and SELP Polymorphisms Predict the Risk of Developing Cachexia in Pancreatic Cancer Patients
por: Avan, Abolfazl, et al.
Publicado: (2014)

USP1 deubiquitinase: cellular functions, regulatory mechanisms and emerging potential as target in cancer therapy
por: García-Santisteban, Iraia, et al.
Publicado: (2013)

Cyclin Dependent Kinase-1 (CDK-1) Inhibition as a Novel Therapeutic Strategy against Pancreatic Ductal Adenocarcinoma (PDAC)
por: Wijnen, Rosa, et al.
Publicado: (2021)

Galectin-4 expression is associated with reduced lymph node metastasis and modulation of Wnt/β-catenin signalling in pancreatic adenocarcinoma
por: Maftouh, Mina, et al.
Publicado: (2014)

Targeting miRNA and using miRNA as potential therapeutic options to bypass resistance in pancreatic ductal adenocarcinoma
por: Vahabi, Mahrou, et al.
Publicado: (2023)

Phospho-Akt overexpression is prognostic and can be used to tailor the synergistic interaction of Akt inhibitors with gemcitabine in pancreatic cancer
por: Massihnia, Daniela, et al.
Publicado: (2017)

Pharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAMM perspective
por: Ciccolini, Joseph, et al.
Publicado: (2016)

Target Therapy in Malignant Pleural Mesothelioma: Hope or Mirage?
por: Borea, Federica, et al.
Publicado: (2023)

CX-5461 Inhibits Pancreatic Ductal Adenocarcinoma Cell Growth, Migration and Induces DNA Damage
por: El Hassouni, Btissame, et al.
Publicado: (2019)

Anaplastic lymphoma kinase inhibition in metastatic non-small cell lung cancer: clinical impact of alectinib
por: Muller, Ittai B, et al.
Publicado: (2017)

A New Oxadiazole-Based Topsentin Derivative Modulates Cyclin-Dependent Kinase 1 Expression and Exerts Cytotoxic Effects on Pancreatic Cancer Cells
por: Pecoraro, Camilla, et al.
Publicado: (2021)

Role of c-MET Inhibitors in Overcoming Drug Resistance in Spheroid Models of Primary Human Pancreatic Cancer and Stellate Cells
por: Firuzi, Omidreza, et al.
Publicado: (2019)

Can cytidine deaminase be used as predictive biomarker for gemcitabine toxicity and response?
por: Peters, Godefridus J., et al.
Publicado: (2019)

New developments in the management of non-small-cell lung cancer, focus on rociletinib: what went wrong?
por: Van Der Steen, Nele, et al.
Publicado: (2016)

Comment on: Targeting the HGF/c-MET pathway in advanced pancreatic cancer: a key element of treatment that limits primary tumour growth and eliminates metastasis
por: Che, Pei Pei, et al.
Publicado: (2020)

Pancreatic cancer resistance conferred by stellate cells: looking for new preclinical models
por: Che, Pei Pei, et al.
Publicado: (2020)

Fungal mycobiome-mediated immune response: a non-negligible promoter in pancreatic oncogenesis and chemoresistance
por: Jiang, Yaling, et al.
Publicado: (2023)

Metabolic Effects of New Glucose Transporter (GLUT-1) and Lactate Dehydrogenase-A (LDH-A) Inhibitors against Chemoresistant Malignant Mesothelioma
por: Franczak, Marika A., et al.
Publicado: (2023)

SF3B1 modulators affect key genes in metastasis and drug influx: a new approach to fight pancreatic cancer chemoresistance
por: Randazzo, Ornella, et al.
Publicado: (2021)

hENT-1 Expression and Localization Predict Outcome After Adjuvant Gemcitabine in Resected Cholangiocarcinoma Patients
por: Meijer, Laura L., et al.
Publicado: (2016)

Interrelationship between miRNA and splicing factors in pancreatic ductal adenocarcinoma
por: Supadmanaba, I Gede Putu, et al.
Publicado: (2021)

A New Twist in Protein Kinase B/Akt Signaling: Role of Altered Cancer Cell Metabolism in Akt-Mediated Therapy Resistance
por: Götting, Isabell, et al.
Publicado: (2020)

Epithelial Transfer of the Tyrosine Kinase Inhibitors Erlotinib, Gefitinib, Afatinib, Crizotinib, Sorafenib, Sunitinib, and Dasatinib: Implications for Clinical Resistance
por: Honeywell, Richard J., et al.
Publicado: (2020)

The allosteric AKT inhibitor MK2206 shows a synergistic interaction with chemotherapy and radiotherapy in glioblastoma spheroid cultures
por: Narayan, Ravi S., et al.
Publicado: (2017)

Transporter and Lysosomal Mediated (Multi)drug Resistance to Tyrosine Kinase Inhibitors and Potential Strategies to Overcome Resistance
por: de Klerk, Daniel J., et al.
Publicado: (2018)

Targeting of the AKT/m-TOR Pathway: Biomarkers of Resistance to Cancer Therapy——AKT/m-TOR Pathway and Resistance to Cancer Therapy
por: SPIRINA, Liudmila V, et al.
Publicado: (2018)

NF-κB drives acquired resistance to a novel mutant-selective EGFR inhibitor
por: Galvani, Elena, et al.
Publicado: (2015)

Better to be alone than in bad company: The antagonistic effect of cisplatin and crizotinib combination therapy in non-small cell lung cancer
por: Van Der Steen, Nele, et al.
Publicado: (2016)

High-Throughput MicroRNA (miRNAs) Arrays Unravel the Prognostic Role of MiR-211 in Pancreatic Cancer
por: Giovannetti, Elisa, et al.
Publicado: (2012)

Targeting PI3K/Akt signal transduction for cancer therapy
por: He, Yan, et al.
Publicado: (2021)

The potential of multi-compound nanoparticles to bypass drug resistance in cancer
por: Da Silva, C. G., et al.
Publicado: (2017)

Targeting Akt in cancer for precision therapy
por: Hua, Hui, et al.
Publicado: (2021)

Role of HGF–MET Signaling in Primary and Acquired Resistance to Targeted Therapies in Cancer
por: Della Corte, Carminia Maria, et al.
Publicado: (2014)

PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma
por: Li, Xiaoman, et al.
Publicado: (2016)

Protective autophagy by thymidine causes resistance to rapamycin in colorectal cancer cells in vitro
por: Bijnsdorp, I.V., et al.
Publicado: (2021)

The Role of Zinc in the Treatment of Wilson’s Disease
por: Avan, Abolfazl, et al.
Publicado: (2022)

Glutamate and α-ketoglutarate: key players in glioma metabolism
por: Maus, Andreas, et al.
Publicado: (2016)

PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
por: Glaviano, Antonino, et al.
Publicado: (2023)

Enhanced efficacy of AKT and FAK kinase combined inhibition in squamous cell lung carcinomas with stable reduction in PTEN
por: Cavazzoni, Andrea, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_bm5p0c5knjka54r6n1r1qau7i1